Myelodysplastic Syndromes: A New Decade

Virginia O. Volpe, Guillermo Garcia-Manero, Rami S. Komrokji

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations

Abstract

Myelodysplastic syndromes (MDS) are a group of heterogeneous clonal hematopoietic stem cell disorders. The 2020 Surveillance, Epidemiology, and End Results data demonstrates the incidence rate of MDS increases with age especially in those greater than 70 years of age. Risk stratification that impact prognosis, survival, and rate of acute myeloid leukemia (AML) transformation in MDS is largely dependent on revised International Prognostic Scoring System along with molecular genetic testing as a supplement. Low risk MDS typically have a more indolent disease course in which treatment is only initiated to ameliorate symptoms of cytopenias. In many, anemia is the most common cytopenia requiring treatment and erythroid stimulating agents, are considered first line. In contrast, high risk MDS tend to behave more aggressively for which treatment should be initiated rapidly with Hypomethylating Agents (HMA) being in the frontline. In those with high risk MDS and eligible, evaluation for allogeneic stem cell transplant should be considered as this is the only potential curative option for MDS. With the use of molecular genetic testing, a personalized approach to therapy in MDS has ensued. As the treatment landscape in MDS continues to flourish with novel targeted agents, we ambitiously seek to improve survival rates especially among the relapsed/refractory and transplant ineligible.

Original languageEnglish (US)
Pages (from-to)1-16
Number of pages16
JournalClinical Lymphoma, Myeloma and Leukemia
Volume22
Issue number1
DOIs
StatePublished - Jan 2022

Keywords

  • High risk
  • Hypomethylating agents
  • IPSS-R
  • Low risk
  • MDS
  • Novel therapies
  • Somatic muations

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Myelodysplastic Syndromes: A New Decade'. Together they form a unique fingerprint.

Cite this